INTRODUCTION: This was a sub-group analysis of patients with uncontrolled persistent allergic asthma (AA) in the healthcare setting of the Czech Republic, from a global non-interventional, 2-year post-marketing, observational eXpeRience registry. AIM: To evaluate the real-life effectiveness and safety of omalizumab. MATERIAL AND METHODS: Patients with uncontrolled persistent AA (currently defined by the Global Initiative for Asthma (GINA) as uncontrolled severe AA) who started omalizumab treatment 15 weeks before inclusion in the registry were analysed for physicians' global evaluation of treatment effectiveness (GETE), asthma symptoms, corticosteroid use, exacerbation rate, asthma control, quality of life, healthcare utilisation and safety during a 24-month observation period. RESULTS: One hundred and fourteen patients from the Czech Republic were enrolled in the eXpeRience registry. A total of 88.9% of the patients were evaluated as responders to omalizumab according to the GETE assessment at week 16. From baseline to month 24: mean change in forced expiratory volume in 1 s (FEV1) was 137 ml and the daily dose of OCS decreased (11.6 mg to 6.4 mg prednisolone equivalent); the percentage of patients with no severe clinically significant exacerbations increased (29.5% to 95.1%); Asthma Control Test scores improved (12.4 to 17.3) and mean total number of days of asthma-related medical healthcare use decreased (6.8 days to 0.4 days). CONCLUSIONS: The results of this subgroup analysis support the evidence that add-on omalizumab therapy is effective and well tolerated for management of patients with uncontrolled persistent AA in the Czech Republic. Global evaluation of treatment effectiveness assessment is a reliable predictor of long-term response to omalizumab treatment.

Department of Pneumology and Phthisiology Charles University Prague Faculty of Medicine in Pilsen Czech Republic

Institute of Clinical Immunology and Allergy Charles University Prague Faculty of Medicine in Hradec Kralove University Hospital in Hradec Kralove Czech Republic

Novartis s r o Prague Czech Republic

Zobrazit více v PubMed

Global strategy for asthma management and prevention 2018. Available from: http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed 23 March 2018.

Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91–8. PubMed

Tuberculosis and respiratory diseases 2014. Available from: http://uzis.cz/system/files/tbc2014.pdf. Accessed 23 March 2018.

Peters SP. Safety of inhaled corticosteroids in the treatment of persistent asthma. J Natl Med Assoc. 2006;98:851–61. PubMed PMC

Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114:40–7. PubMed

Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66:671–8. PubMed

Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–16. PubMed

Siergiejko Z, Swiebocka E, Smith N, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27:2223–8. PubMed

Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42:1224–33. PubMed

Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103:1725–31. PubMed

Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50:529–36. PubMed PMC

Kuprys-Lipinska I, Molinska K, Kuna P. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. Pneumonol Alergol Pol. 2016;84:232–43. PubMed

Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107:1141–51. PubMed

Braunstahl GJ, Leo J, Thirlwell J, et al. Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Curr Med Res Opin. 2011;27:761–7. PubMed

Summary of Product Characteristics [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf]. Accessed 23 March 2018.

Ehrs PO, Nokela M, Stallberg B, et al. Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. Chest. 2006;129:925–32. PubMed

Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65. PubMed

Lloyd A, Turk F, Leighton T, Canonica GW. Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ. 2007;10:285–96.

Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124:719–23 e1. PubMed

Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14:32–8. PubMed

Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81–7. PubMed

Sedlák V, Chlumský J, Teřl M, et al. Doporučený postup diagnostiky a léčby obtížně léčitelného bronchiálního astmatu. 2016. Available from: http://www.pneumologie.cz/guidelines. Accessed 23 March 2018 (National Severe Asthma Guidelines in Czech)

Terl M, Sedlak V, Cap P, et al. Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy. Allergy. 2017;72:1279–87. PubMed

Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–207. PubMed

Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012;6:215–27. PubMed

Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103:1633–42. PubMed

Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104:1410–6. PubMed

Menzella F, Galeone C, Formisano D, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res. 2017;9:368–72. PubMed PMC

Kuprys-Lipinska I, Majak P, Molinska J, Kuna P. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med. 2016;16:61. PubMed PMC

Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140:162–9.e2. PubMed

Kuprys-Lipinska I, Kuna P. Loss of asthma control after cessation of omalizumab treatment: real life data. Postep Dermatol Alergol. 2014;31:1–5. PubMed PMC

Hutyrova B, Bystron J, Chlumsky J, et al. Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry. Eur Respir J. 2017;50(Suppl 61):PA3541. PubMed PMC

Novelli F, Latorre M, Vergura L, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:123–9. PubMed

Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012;49:144–52. PubMed

Braunstahl GJ, Canvin J, Peachey G, et al. Healthcare resource utilization in patients receiving omalizumab for allergic asthma in a real-world setting. Biol Ther. 2014;4:57–67. PubMed PMC

Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39:788–97. PubMed

Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27:163–9. PubMed

Bronchial Asthma as a Cardiovascular Risk Factor: A Prospective Observational Study

Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?